Kim YH, Bagot M, Pinter-Brown L, et al. Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study. ASH 59th Annual Meeting & Exhibition, abstract 817.
Eerder behandelen met ruxolitinib lijkt overlevingsvoordeel van MF-patiënten met int-2 of hoog risico te vergroten
okt 2017 | MPN